INTRODUCTION
Atherosclerosis is an inflammatory disease in which lesions or plaques build up in arteries [1] [2] .
The first step in the development of atherosclerotic lesions is the activation of cells in blood-vessel walls, such as endothelial cells [3] [4] . It is well known that the endothelium is directly involved in vascular disease, stroke, heart disease, and diabetes [5] . Especially, diabetes has been reported to increase the risk of cardiovascular disease by accelerating the formation of atherosclerosis [6] . Diabetes-associated atherosclerosis and vascular diseases are the principal causes of morbidity and mortality in patients with diabetes [7] .
Lysophosphatidic acid (LPA) is a bioactive lipid that is produced in serum after the activation of multiple biochemical pathways [8] [9] . Some clinical studies have reported that the plasma LPA level is correlated with vascular diseases and some species of LPA induce neointima formation, which is a characteristic feature of common vascular pathologies such as atherosclerosis. However, previous reports stated that neointima formation induced by unsaturated LPA is not mediated by LPA 1 and LPA2 receptors that are the major LPA-receptor subtypes of the G-protein coupled receptors (GPCRs) expressed in bloodvessel walls [10] . Thus numerous factors contribute to atherosclerosis, a complex disease that is accelerated by diabetes and metabolic syndrome. Moreover, because metabolic syndrome occurs commonly in people with type II diabetes which most of the increased incidence of cardiovascular diseases [11] [12] .
We previously reported that unsaturated LPA species induced arterial-wall remodeling in rat and mouse non-injury model, and this response required peroxisome proliferator-activated receptor gamma (PPARγ) [13] . The function of PPARγ has been studied extensively, and a variety of synthetic and physiological agonists of this receptor have been identified [14] , including thiazolidinediones (TZDs) and numerous natural ligands containing fatty acids and phospholipids [14] . Recently, selected phospholipid such as LPA and alkyl-glycerophosphate (AGP, also known as alkyl-LPA) were identified as agonists of cPA regulates AGP-elicited VEGF secretion 5 PPARγ (Fig.1) [15] [16] . Later, we reported that AGP is a specific high-affinity and more potent agonist of PPARγ than LPA. Fujiwara and colleagues reported that AGP, an analog of LPA, is a weak agonist of LPA receptors except LPA5 receptor, however, only LPA5 receptor shows a preference for AGP than LPA [20] . Interestingly, AGP has a higher potency than LPA with respect to PPARγ activation [16] . Binding studies using the PPARγ ligand-binding domain showed that binding study of the AGP was similar to that of the TZD rosiglitazone [16] . We recently identified cyclic phosphatidic acid (cPA) is an endogenous PPARγ antagonist, and it is generated by phospholipase D2 (PLD2) [13] . These observations suggest that activation of PPARγ is likely to lead to a complex cellular response.
Earlier studies have shown that PPARγ, which plays a key role in the cardiovascular system, is expressed in all cell types of the blood-vessel wall and in monocytes and macrophages [21] . Coronary artery disease is the most common type of heart disease, and the leading cause of death from cardiovascular diseases is typically the result of atherosclerosis [22] . Our results thus raise the possibility of using cPA as a lead compound to develop new treatments that act on PPARγ. However, the critical genes affected by the cPA-mediated inhibition in the endothelial cells of the coronary artery remain unknown. The migration of endothelial cells contributes to diverse aspects of vascular physiology such as the development of atherosclerosis. Currently, cPA plays a role in the anti-neointima activity of carotid arteries [13] ; and, thus, it is important to understand the mechanisms that determine cPA sensitivity.
Here, we are focusing on the regulation of the vascular endothelial growth factor (VEGF) regulation induced by cPA. VEGF is a growth factor that was first identified to be specific to the vascular endothelium [23] . In mammals, the VEGF family consists of five members, VEGF-A, VEGF-B, VEGF-C, VEGF-D and the placenta growth factor (PLGF) [24] . VEGF is a potent mitogen and angiogenic growth factor that is the most critical regulator of vascular development [23] . Previously, VEGF was shown to play a role in endothelial cell proliferation, migration, and atherosclerosis [25] . Several studies have demonstrated that PPARγ agonists regulate the expression of various genes including VEGF and its receptors [26] . Rosiglitazone, one of TZDs and a synthetic agonist of PPARγ, has been reported to suppresses VEGF expression through a PPARγ-responsive element in the promoter of the VEGF gene, cPA regulates AGP-elicited VEGF secretion 6 and pioglitazone, another synthetic agonist of PPARγ, was reported to decrease VEGF expression [27] .
On the contrary, other studies have reported that TZD drugs increase VEGF expression [26] .
In diabetes, a key factor could be the potential involvement of VEGF in the development of atherosclerosis in patients with diabetes [28] . The discrepancies in the aforementioned results may have arisen from the use of distinct cell types, but the exact mechanisms remain unknown. Moreover, although cPA can arrest the growth of cells, including diabetic human coronary artery endothelial cells (DHCAECs), the relationship between the anti-cell growth effect of cPA and the regulation of VEGF expression is unknown. In this study, we determined that the PPARγ antagonist cPA potently inhibited the release of VEGF protein into the media which express high levels of PPARγ in D-HCAECs. The reduction in VEGF expression and secretion was linked to a decrease in the expression of the mRNA and the transcriptional inactivation of the VEGF promoter. We conclude that the inhibition of PPARγ downregulates VEGF expression and that this may be involved in the regulation of D-HCAECs proliferation and migration. for 10 min (polymerase activation), followed by 40 cycles of 95°C for 15 s, 55°C for 15 s, and 72°C for 30 s. To identify the housekeeping genes that were most suitable for normalizing the data, we initially used a human housekeeping gene primer set (TAKARA). After amplification, the samples were slowly heated from 55°C to 95°C and fluorescence was measured continuously to obtain a melting curve. The relative mRNA levels were quantified by using the formula 2 -ΔΔCq , where ΔCq is the difference between the threshold cycle of a target cDNA and an endogenous reference cDNA.
EXPERIMENTAL PROCEDURES

Materials -
Small interfering RNAs -The expression of PPARγ and VEGF in HCAECs and D-HCAECs was
inhibited by transfecting with siRNAs targeted to PPARγ and VEGF (Santa Cruz Biotechnology) by using Lipofectamine RNAiMAX (Invitrogen). Cells were cultured in 6-well plates (Iwaki, Tokyo, Japan) at a density of 5 × 10 4 cells/well in DMEM containing 10% FBS. Cells were transfected with 100 pmol/mL of mRNA-specific siRNAs or a scrambled control siRNA. The reduction in PPARγ levels was confirmed using western blotting analysis. Wound-healing assay -Cell-migration assays were performed using μ-Dish 35 mm culture inserts (Ibidi, Immediately after removing the inserts (0 h) and at 3 and 6 h, cultures were photographed using phasecontrast microscopy, and the widths of wounds were measured to calculate the mean percentage of closure under each culture condition.
Measurement of cell proliferation -
Assessment of VEGF secretion by D-HCAECs and HCAECs in vitro -
Cells were seeded in 60 mm dishes at a density of 5 × 10 4 cells/dish and incubated in 10% FBS containing medium overnight, followed by incubation in serum-free medium for 24 h. Levels of human VEGF in the samples were determined by performing a sandwich enzyme immunoassay by using a human VEGF Assay Kit-IBL (ImmunoBiological Laboratories, Fujioka, Japan).
Statistical analysis -Student's t test was used for statistical comparisons and p < 0.05 was considered statistically significant.
RESULTS
Humans express two PPARγ isoforms, PPARγ1 and PPARγ2 originated from alternative splicing [29] . We first examined the mRNA expression level of PPARγ1 and PPARγ2 in HCAECs and D-HCAECs.
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As shown in Figure 2A , PPARγ1 mRNA was expressed at higher levels in D-HCAECs than in HCAECs.
In contrast to PPARγ1, we did not detect the expression of PPARγ2 mRNA in the both cell types/lines. We next investigated PPARγ protein expression levels in the cells (Fig. 2B) . We observed that the two primary cell lines expressed distinct levels of PPARγ1, however, PPARγ2 was hardly detectable. The expression levels of PPARγ1 and PPARγ2 proteins agreed well with those of the mRNAs expression.
However, in D-HCAECs, treatment with AGP and cPA did not alter PPARγ mRNA expression for 24 h (Fig. 3B) . To test the function of the PPARγ receptor, we transfected the cells with a luciferase reporter plasmid. Interestingly, luciferase activity increased only in D-HCAECs after exposure to AGP (Fig.3C) . Next, to establish that none of the six known LPA receptors (LPA1-6) is required for activation of PPARγ, we confirmed the expression levels of LPA1-6 mRNAs in HCAECs and D-HCAECs. As shown in Figure 3C , only LPA4 mRNA was highly expressed in the two cell lines, and the expression of this receptor in D-HCAECs was significantly greater than that in HCAECs. To examine the differences in LPA4 activation in response to cPA and AGP, we obtained full dose-response curves of the activation of LPA4 by cPA and AGP in D-HCAECs. Previous report suggested that cPA is a weak agonist of LPA4 and it has a significantly higher EC50 than LPA and AGP [30] . Furthermore, the endogenous PPARγ antagonist cPA inhibited the enhanced activation of PPARγ activation elicited by AGP. We found that these two cell types expresse high levels of LPA4 (Fig. 3D) . For this reason, we also tested the ligand properties of AGP (18:1) and cPA (18:1) on LPA4. As shown in Fig. 3D , although AGP 18:1 activated LPA4, cPA 18:1 was no response up to 10 μM in LPA4 overexpressing cells. These results suggest that cPA might not be associated with LPA4 receptor in D-HCAEC cells.
We next investigated the effect of the growth properties of HCAECs. As shown in Figure 4A , DHCAECs obtained from diabetic donors grew faster than the HCAECs obtained from healthy donors; D-HCAEC cell numbers were significantly higher than HCAEC cell after 24 h incubation using medium containing 5% FBS and the manufacturer-recommend supplemental growth factors. We next investigated cPA regulates AGP-elicited VEGF secretion 11 the effect of cPA on the growth in HCAECs. cPA did not affect on the growth in HCAECs (Fig.4B) .
however, cPA induced cell growth in a time-dependent manner in D-HCAECs (Fig.4C ). D-HCAECs showed more responsive to cPA than HCAECs (Figs. 4B and 4C ). These data suggest that the altered growth properties of the cells obtained from the diabetic donors may represent a requisite feature of the diabetic status. To evaluate how PPARγ affects the growth of D-HCAECs, PPARγ expression was knocked down using siRNAs (Fig.4F ) (it should be 4D). PPARγ-siRNA efficiently reduced the protein expression (Fig.4X) . As shown in Figure 4D , and 4E, cell growth increased after transfection with PPARγ-siRNA, an effect that was not observed using the control siRNA. These results demonstrate that (Fig. 5B) . Furthermore, the synthetic PPARγ antagonist T0070907 strongly inhibited cell migration. To evaluate the effects of PPARγ on the migration of D-HCAECs, PPARγ expression was knocked down using siRNAs. As shown in Figure 5C , cell migration increased after transfection with the siRNA targeting PPARγ but not the control siRNA.
These results suggest that PPARγ inhibition strongly influences D-HCAEC migration.
VEGF is a potent inducer of endothelial cell proliferation and migration [31] . Noteworthy, VEGF also induces expression of IL-6, and IL-8 in endothelial cell [32] [33]. We performed real-time PCR analysis to determine whether lysophospholipids PPARγ ligands affects the levels of VEGF mRNA in vitro. As shown in Fig. 6A , VEGF mRNA levels in D-HCAECs were markedly enhanced after treatment cPA regulates AGP-elicited VEGF secretion 12 with 1 μM AGP and further increased when 10 μM AGP was added; these are the concentrations of AGP that are present physiologically [16] . Furthermore, LPA also increased VEGF mRNA levels in DHCAECs in a dose-dependent manner (Fig. 6A) . Interestingly, real-time PCR analysis revealed that, in DHCAECs, cPA decreased VEGF mRNA expression (Fig.6A) . To determine how VEGF secretion is stimulated, HCAECs and D-HCAECs were incubated in the absence or presence of 1, 3, and 10 μM AGP and then conditioned media were assayed for secreted VEGF by performing ELISAs. As shown in Fig. 6B, AGP were significantly increased VEGF secretion dose-dependently in D-HCAECs.
Representative results are shown in Figure 6C , which demonstrate that AGP and LPA but not cPA strongly induced VEGF secretion by D-HCAECs; cPA at concentrations as high as 1, 3, and 10 μM failed to induce VEGF secretion, whereas AGP and LPA increased VEGF secretion by D-HCAECs in a dosedependent manner (Fig. 6C ). These data suggest that exogenously applied cPA inhibited VEGF secretion elicited by LPA or AGP. Next, we determined effect of PPARγ ligands on the activity of the VEGF gene promoter (Fig. 6D) . The cells were transfected with a reporter plasmid containing the VEGF promoter and then incubated with AGP or cPA. In D-HCAECs, the promoter activity was substantially enhanced compared with that in HCAECs after treatment with AGP but not cPA. Intriguingly, cPA inhibited the VEGF-promoter activation induced by AGP.
These data suggest that the effect of the PPARγ antagonist cPA on VEGF mRNA expression is mediated at least partly by a decrease in the rate of transcription from the VEGF promoter. We also explored the influence of VEGF per se on the growth of D-HCAECs. As shown in Figure 6E , cPA inhibited exogenously added VEGF enhanced D-HCAEC growth. Furthermore, transfection of DHCAECs with control or VEGF siRNA revealed that the VEGF knockdown ( Fig.7A and B ) attenuated AGP-induced VEGF secretion (Fig. 7C ) and cell growth promotion (Fig. 7D) . Furthermore, as shown in cPA regulates AGP-elicited VEGF secretion
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DISCUSSION
Diabetes patients have been reported to have a 2-to 4-fold increased risk of developing atherosclerotic coronary artery disease [34] . Endothelial dysfunction has been suggested to be an early event in diabetic atherosclerosis, and this dysfunction is associated with atherosclerotic coronary artery disease risk [35] . Brief exposure to AGP has been reported to induce progressive neointima formation [10] and, recently, LPA and its analog were shown to stimulate a new type of signaling by directly activating PPARγ [15] . A previous report suggested that neointima formation elicited by unsaturated LPA is not mediated by the LPA receptors (GPCRs) expressed in blood-vessel walls [13] ; however, topical application of unsaturated LPA species into the non-injured carotid artery of rodents induced arterial-wall remodeling [13] , and this response required PPARγ. LPA and AGP have also been reported to be agonists of PPARγ and have been implicated in atherogenesis [10] . When AGP was infused to an injured carotid artery, neointimal thickening was augmented, whereas the TZD drug rosiglitazone attenuated neointimal thickening induced by mechanical injury. However, in a non-injury model, rosiglitazone induced neointima formation when applied intraluminally into the carotid artery [13] . Thus,
AGP, but not rosiglitazone, increased injury-induced neointima formation, indicating that AGP-mediated
PPARγ activation plays a role in vascular remodeling following vascular injury [13] .
PPARγ is a member of the nuclear receptor gene family that plays a central role in the regulation of glucose and lipid homeostasis [36] . PPARγ plays a critical role in the cardiovascular system, and it is expressed in all cell types of the vessel wall, as well as in monocytes and macrophages [37] . PPARγ agonists promote adipocytic differentiation and stimulate the uptake of low-density lipoprotein by macrophages, leading to foam-cell formation in the arterial wall [38] . Considerable evidence suggests that oxidized phospholipids and fatty acids function as deleterious signaling molecules in the context of atherosclerosis lesion formation [39] . We recently determined that the production of cPA inhibits the transcription of PPARγ-target genes that normally drive adipocytic differentiation, lipid accumulation in macrophages, and arterial-wall remodeling; our recent work suggests that the endogenous LPA analog cPA regulates AGP-elicited VEGF secretion 14 cPA is a bona-fide second messenger and a physiological inhibitor of PPARγ [13] . However, the specific effects of diabetes on the function of the coronary endothelium are not well defined.
In this study, we determined that the growth and migration of human coronary endothelial cells obtained from donors with type II diabetes and the suppressive effects of the phospholipid cPA require the inhibition of PPARγ (Fig.8) . Furthermore, our results have demonstrated that, in HCAECs isolated from diabetes patients, which expressed PPARγ at high levels, VEGF production was elicited by AGP.
We have shown that treatment with the PPARγ antagonist cPA diminished the synthesis of VEGF, which
suggests that cPA inhibition of VEGF synthesis can affect the vessel wall by influencing endothelial cell growth and migration. Conversely, AGP, the high-affinity natural ligand of PPARγ [16] , effectively increased VEGF mRNA expression and protein release. The VEGF promoter, however, does not contain the PPRE motif; thus, cPA appears to downregulate VEGF expression indirectly, and the reduction in the synthesis of mRNA and protein probably depends partly on the inhibition of the VEGF promoter. Several studies have reported increased levels of VEGF in the serum of patients with acute coronary syndrome [40] . Atherosclerosis is the most common type of heart disease and the leading cause of death resulting from cardiovascular diseases. In addition, previous report suggests that VEGF appears to play a central role in mediating diabetic endothelial dysfunction. [41] . Thus, the results of this study raise the possibility of using cPA as a lead compound to develop new treatments that act on PPARγ; however, further investigation is required to determine the molecular mechanisms underlying the described effect of cPA.
cPA regulates AGP-elicited VEGF secretion cPA is a naturally occurring acyl analog of LPA. cPA is a weak agonist of plasma membrane LPA receptors, whereas cPA is an inhibitor of PPARγ. and cPA (10 μM) were added to the medium, and the cells were incubated for 12 h. The amount of orange formazan dye generated was determined by measuring the absorbance at 450 nm in a microplate reader.
Data are expressed as mean ± SEM (n = 3), **p < 0.01. Data represent the mean ± SE of triplicate independent experiments (*P < 0.05 and **P < 0.01 vs.
vehicle-treated controls). These results suggest that cPA suppresses VEGF-stimulated growth and migration in D-HCAECs.
